Biotechnology in Taiwan

Hi-Q Marine Biotech International Ltd

Hi-Q Marine Biotech is founded in 1998, a leading marine biotechnology company in Taiwan. Hi-Q specializes in the research and development of Low Molecular Weight Fucoidan (Oligo Fucoidan), a type of clinically-proven ingredient extracted from natural brown seaweed, developed specifically for nutritional, cosmetic and animal health applications. With the passion of ‘empowering people to lead healthier lives’, Hi-Q are investing in development of cancer nutrition to fulfill the ongoing need to proper and adjunct nutrition to cancer patients as they suffer from cachexia. In addition to the own expert teams, Hi-Q collaborates with leading research institutions for advanced research and solution.#Hi-Q #FucoHiQ #Taiwan #cancer #oncology #nutrition #dietarysupplement #functionalingredients #skincare #cosmeticingredient #kelp #brownseaweed #algae #marine

51 to 200 staff

Rakuten Medical

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox® platform, which has been shown to induce rapid and selective cell killing and tumor necrosis. Rakuten Medical is committed to its mission to conquer cancer by delivering its innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit

51 to 200 staff

Fidelity Regulation Therapeutics

Fidelity Regulation Therapeutics Inc, FRT, is a drug development company. Based on the biomedical and basic scientific background, FRT is committed to develop drugs to fulfill unmet medical needs.

1 to 10 staff

Apex Biotechnology Corp 1733

1 to 10 staff

Eiffel Biotech

Since our establishment in 2011, Eiffel Biotech Co, Ltd. has been committed to the development and manufacturing of Nattokinase. We supply all kinds of high-activity Nattokinase raw materials and various Nattokinase related products for major pharmaceutical factories and health food factories. Our Nattokinase activity can reach Fu/g, Fu/g, and even Fu/g. We successfully sold to the mainland, the United States, Japan, and Asian countries. The products are trusted and loved by customers.

11 to 50 staff

Development Center For Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. The division of Industrial Promotion provides industrial information, services, facilitates technology transfer, and overall foster international partnerships for commercialization. Many of these functions are performed in conjunction with outpost team members managing other government-sponsored programs, such as the Biotechnology and Pharmaceutical Industries Program Office (BPIPO; commissioned by the Industrial Development Bureau, MOEA), and the Nankang Biotech Incubation Center (NBIC; commissioned by the Small and Medium Enterprise Administration, MOEA). DCB is dedicated to R&D in botanic drug products, pharmaceuticals, biologics, animal pharmacology, and innovative and explorative research. DCB also establishes itself as a licensing technology platform. At present, the therapeutic areas for drug development include cancer, diabetes, as well as infectious, inflammatory and cardiovascular diseases.

201 to 500 staff

Amwise Diagnostic Pte. Ltd

About Amwise Diagnostic We are a leader in precision medicine technology for cancer. Our patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy that has optimal treatment effectiveness and minimal treatment-related adverse events. Unlike current diagnostic techniques, our innovative technology identifies patients who have a definite high risk of recurrence or metastasis, allowing timely administration of necessary treatment. Our existing product assesses an individual breast cancer patient's need for adjuvant treatment with radiation therapy or chemotherapy. In addition, we have expanded our research into the field of colorectal cancer with the hope of helping more cancer patients in the future. Through strategic partnerships and investment links, we have formulated our plans for the Asian region and have started to plan our entrance into Europe and the United States. We envision our technology benefiting a greater number of patients, leading precision medicine in cancer to the next milestone. About RecurIndex® RecurIndex®, which has undergone large-scale clinical validation, integrates genetic mapping of the genes most related to breast cancer recurrence in Asian patients with clinical factors to predict the 5-year risk of local recurrence and distant metastasis. The test results can help doctors and patients have an earlier understanding of cancer characteristics and can serve as an important reference in the determination of appropriate treatment.

11 to 50 staff

Anbogen Therapeutics

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs. Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development.

11 to 50 staff

Senhwa Biosciences, Inc

Senhwa (6492, TWO) is a precision therapy company dedicated to developing First-in-Class therapeutics targeting oncology, rare diseases, and immunotherapy. Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan. Senhwa’s CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwa's CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair protein XRCC1 and subsequently enhance the activity of DNA damaging chemotherapy agents. Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.

11 to 50 staff

A2 Healthcare Taiwan Corporation

As a member of ITOCHU Group, A2 Healthcare Corporation contributes to the research and development of medical and pharmaceutical products through sophisticated offering of clinical research full services with footprints in the US and Asia. In particular, A2 Healthcare specializes in early phase clinical trials, serving hundreds of clients in Taiwan (86%) and worldwide (14%).

51 to 200 staff

Atgenomix

Atgenomix is a data and machine learning (ML) company that provides an open standard and unified platform for operationalizing biomedical data, analytics, and ML to deliver on the promise of precision medicine. The Atgenomix cloud-based biomedical informatics platform empowers clinical laboratories to design, develop, and operate GA4GH (Global Alliance for Genomics & Health) standard orchestrated multimodal workflows of data integration, tool engineering, analysis automation, workload acceleration, and regulatory compliance management. At Atgenomix, we envision a technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide industry accessible computational lab technologies that researchers need to scale data and machine learning in the future. Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, and a Google Health trusted partner in genomics research.

11 to 50 staff

Strong Biotech Corporation

Combined with professionals in clinical gastroenterology, Strong developed Helicobacter pylori in vitro diagnostic devices and related biotech materials. Strong is Taiwan and the world’s first company specializing in producing both paper and gel type Helicobacter pylori in vitro diagnostic test, providing rapid diagnosis of peptic ulcer caused by the H. pylori as the basis of doctor’s prescription.

11 to 50 staff

Sunway Biotech Co., Ltd

Founded in 2007, SunWay Biotech specializes in advanced microbiological technology and patented fermentation processes. We offer end-to-end solutions, including innovative ingredient development and sales, CDMO/CMO contract manufacturing, proprietary branded products, and brand licensing services. With a strong commitment to scientific validation and product quality, we strive to bring innovative health solutions to global markets, fulfilling our mission:"Make health part of everyday life and unlock infinite possibilities."

51 to 200 staff

Aidmics Biotechnology

Aidmics Biotechnology dedicates itself to providing solutions in microscopic scales. Ever since the launch of its very first product, the iSperm Analyzer, Aidmics has received attentions from across the world, including Reuters, Fast Company, among others.

11 to 50 staff

Aquavan Technology Co., Ltd

Aquavan Technology extracts global functional herbal materials and preserve the valuable ingredients which are healthy and nutritional to people via the cutting-edged extraction technology: Supercritical Fluid Extraction. Aquavan also exclusively selected the most precious “No. 4 Hualien Kakorot” cultivated by Taiwan government and Organic farming. Aquavan also established two sub-brands, Tsuie and Axtract in order to provide different aspects of product solutions and approach various type of targeted customers. Tsuie, the brand of nutraceutical products, means the life essences extracted from plants and obtained the nutrition from the daily sunshine, and wish to deliver the most effective and high-quality solutions to the world and make people healthier. Axtract is another brand to promote the extractions from global functional herbal materials, and aims to approach the distributors of extracted materials, and manufactures of herbal nutraceutical products worldwide.

51 to 200 staff

Genomics Biosci & Tech Co Ltd

Genomics BioSci & Tech. Co, Ltd. is dedicated to advancing our understanding of genomes, with a focus on their structure, function, evolution, mapping, and editing. We specialize in cutting-edge sequencing technology, bioinformatics, and synthetic biology, enabling us to precisely assemble and analyze gene function and structure. Our services and products empower scientists to tackle real-world challenges, including increasing crop yields through genetically modified plants, developing new drugs, detecting diseases, and providing precision medicine strategies. As Taiwan's premier commercial sequencing company, with over 20 years of expertise in genomic science, Genomics BioSci & Tech. Co, Ltd. has a robust foundation in sequencing services, oligo, and peptide synthesis. We collaborate with leading academic institutions and biotech partners to develop accurate medical genetic testing, offer personalized medical information, and contribute to government research projects aimed at advancing agriculture." Pioneering a new frontier in biotech through sequencing, innovating genetics with cutting-edge cloud solutions." — Dr. Teh-Yuan Chow

51 to 200 staff

Leon Biotech. Co., Ltd

Leon Biotech is established in 2011 as a leading Asia, Taiwan-based Preclinical Contract Research Organization (CRO) providing Integrated Testing & Regulatory Services for medical device companies. We have a state of the art facility with OECD GLP and ISO 17025 accredited, and multiple discipline portfolio service scope; include medical device biocompatibility study; health food toxicology study and consulting. Our team features *Comprehensive one-stop service *Product registration and testing service *Medical device Worldwide Service (European, America, China, Taiwan)*Experts across five industries (pharmaceutical, medical device, cosmetic, food, chemical)

51 to 200 staff

Magqu Co., Ltd

MagQu focuses on creating new technologies and novel products. To do this, MagQu forms an interdisciplinary R&D team, as well as cooperates with professional institutes or experts in the areas of bio-chemistry, protein, nanomaterials, magnetism, electric engineering, software programming, laboratory medicine, clinic medicine, aquaculture etc. So far, MagQu has created more than six innovative technologies and has made them commercialized. Through the marketing of these novel products, we continuously increases its value, and keeps itself at the leading position in the relevant markets. We have utilized our core technology, so-called ImmunoMagnetic Reduction (IMR), to develop dozens of products, such as in-vitro diagnostic (IVD) assay kits and analyzers for colorectal cancer, Alzheimer’s disease, Down’s syndrome, preterm birth, inflammatory disease, grouper viruses etc. The R&D and manufacture of products have been certified with both ISO including 9001 and 13485, and GMP. We successfully made them on the shelf for life-science markets in China, Japan, Korea, Malaysia, Turkey, USA, UK, and Germany.

11 to 50 staff

Tools

To accomplish your research work more efficient, we provide "TOOLS" to fulfill all of your creativity needs."TOOLS" specializes in bringing scientists "total solution" products for all applications of biomedical research from DNA to proteins including molecular biology reagents (immunology, PCR, qPCR and nucleic acid purification kits etc.), customized products and services (miRNA mimics and inhibitors, siRNA synthesis and peptide synthesis). Our enthusiastic and professional team is able to offer the right tools to distributors, OEM resellers and researchers with competitive product pricing. Moreover, providing the right information and useful suggestions to researchers are the core values of "TOOLS".

51 to 200 staff

Energenesis Biomedical

Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases. Pipeline: ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase recruiting in the US and Taiwan) ENERGI-F701: hair tonic for Alopecia (Phase II, completed) ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD & RPD) ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)

11 to 50 staff

Lifeos Genomics

LifeOS Genomics was founded in 2015 on the vision of enabling accessible testing for genetic diseases. To realize this vision, we built the QLoci™ system, a fully automated “sample-to-result” molecular screening platform that offers proprietary multiplex digital PCR (mdPCR™) technology. The breakthrough of our mdPCR™ platform is the marriage of up to 100-plex assay capability in a digital PCR-on-chip format and 0.01% sensitivity, all delivered in a single microfluidic cartridge. This unique ability to provide high multiplicity assays and absolute quantitation with remarkable consistency is a game changer in fulfilling unmet medical needs, particularly in early detection and dynamic therapeutic solutions.

11 to 50 staff

Lucky Flowers Guann-Haw Biotech Corp

Our company is responsible for the lucky flowers anti-mold products business development, marketing, import and export of goods. Lucky flowers anti-mold products including anti-mold stickers and anti-mold packets and so on. Lucky flowers registered trademark and patents worldwide. Lucky flowers run business with Customers all over the world and stand out in the market of anti-mold products. In consideration of the raising trend of green product, lucky flowers correspond with EU biocidal product regulation (BPR). The summit new substance is on the article 95 list since May 2015 and EU REACH pre-registration. lucky flowers product meet SGS ITSTUV…world-famous certification company and test such as: REACH SVHC, DMF free and Rohs. Lucky flowers are a green environmentally friendly high-tech product which can be use wide industries.

11 to 50 staff

T-E Pharma

T-E Pharma Holding owns two subsidiaries: Immunwork, Inc. and T-E Meds, Inc. Immunwork, founded in 2014, is dedicated to the research, development and commercialization of innovative therapeutics based on our proprietary “T-E pharmaceuticals” platform. The drug-design platform is employed in the construction of ultra-long-acting peptide therapeutics, antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and other advanced pharmaceutical modalities. To focus development efforts in the ADC/ARC field, Immunwork established T-E Meds, Inc. in 2022 to take over and further develop its ADC and ARC platforms and associated drug candidates. Among our leading clinical assets, TE-8214 and TE-8105, both developed using its ultra-long-acting platform, represent key milestones. TE-8214, targeting neuroendocrine tumors and acromegaly, successfully completed its Phase I trial in June 2025. TE-8105, aimed at treating obesity (including weight management), type 2 diabetes, and fatty liver disease, completed its Phase I/IIA trial in November 2025. Both candidates have demonstrated good tolerability with no significant side effects. Phase II trials are currently in active preparation. T-E Meds, founded in 2022, focuses exclusively on antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Unlike conventional ADC/ARC platforms that often suffer from low product homogeneity and complex manufacturing processes, T-E Meds employs a proprietary bioconjugation platform that enables streamlined, enzyme-free, site-specific conjugation. This approach yields homogeneous ADCs/ARCs with high drug-to-antibody ratio (DAR), excellent yield, high purity, and flexible payload incorporation. T-E Meds is advancing a robust pipeline of preclinical candidates targeting various cancers, with IND filings for lead candidate planned in 2026 H1.

11 to 50 staff

Aeon Biotherapeutics Corp

We believe the only way to the highest quality of life is to have a healthy body and mind. Knowing that all of our patients have unlimited regenerative potentials, we integrate technologies into medicine to develop safer and more efficient therapies to facilitate natural healing processes and strengthen bodily functions. Biological changes will keep on influencing our daily lives; thus, we have begun a never ending quest to explore new solutions. We are Aeon Biotherapeutics and we are dedicated to creating healthier possibilities.

11 to 50 staff